A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus
Status:
Recruiting
Trial end date:
2027-11-13
Target enrollment:
Participant gender:
Summary
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and
safety of obinutuzumab versus placebo in participants with active, autoantibody-positive
systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.